Corporate Profile

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of patients with rare diseases. As a leader in structure-guided drug design, BioCryst leverages its more than 35 years of expertise in the integrated application of traditional biology and medicinal chemistry to design novel molecules that are potent, selective, and bioavailable to target difficult-to-treat diseases. BioCryst commercialized the first oral, once-daily prophylactic therapy for hereditary angioedema and is advancing a pipeline led by a factor D inhibitor targeting complement-mediated diseases.